论文部分内容阅读
目的探讨药盒在晚期原发性肝癌治疗中的临床价值。方法无外科手术及动脉栓塞指征的８２例晚期原发性肝癌，依据动脉内化疗方式不同，分为两组：Ａ组４２例，采取经皮经股动脉植入药盒，术后经药盒１周或２周化疗１次；Ｂ组４０例，采取每个月１次插管大剂量化疗。结果Ａ、Ｂ两组有效率（ＣＲ＋ＰＲ）分别为３８．１％和１５．０％（Ｐ＜０．０５）。Ａ组６个月、１年、２年生存率分别为６１．９％、２８．６％、９．５％；Ｂ组分别为２０％、５％、０％（Ｐ＜０．０１）。Ａ组患者的生存质量明显改善，消化道反应、肝、胆、骨髓毒性均较Ｂ组低。结论经药盒间断性化疗并配合地塞米松治疗晚期原发性肝癌可明显改善患者的生存质量，提高生存率。
Objective To explore the clinical value of the kit in the treatment of advanced primary liver cancer. Methods Eighty-two cases of advanced primary liver cancer without surgery and arterial embolism were divided into two groups according to different intra-arterial chemotherapy. 42 cases in group A were treated with percutaneous transfemoral implant kit. Box 1 or 2 weeks of chemotherapy; 40 patients in group B, taking high-dose chemotherapy intubation once a month. Results The effective rates (CR+PR) of A and B groups were 38.1% and 15.0%, respectively (P<0.05). The 6-month, 1-year, and 2-year survival rates in group A were 61.9%, 28.6%, and 9.5%, respectively; those in group B were 20%, 5%, and 0%, respectively (P < 0.01). The quality of life in group A was significantly improved, and gastrointestinal reactions, liver, gallbladder and bone marrow toxicity were all lower than in group B. Conclusion Intermittent chemotherapy with drug box and dexamethasone for advanced primary liver cancer can significantly improve the quality of life of patients and improve survival.